| Frecuencia de malformaciones congénitas: evaluación y pronóstico de 52.744 nacimientos en tres ciudades colombianas I Zarante, L Franco, C López, N Fernández Biomédica 30 (1), 65-71, 2010 | 158 | 2010 |
| Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia F Hernández, P Lasalvia, J Garzón, C Castañeda-Cardona, C López, ... Infectio 24 (1), 9-14, 2020 | 2 | 2020 |
| 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries MF Mojica, R Rios, E De La Cadena, A Correa, L Diaz, LV Millan, ... Open Forum Infectious Diseases 6 (Supplement_2), S285-S286, 2019 | 1 | 2019 |
| 2477. Antimicrobial Resistance patterns of Enterobacteriaceae and Pseudomonas aeruginosa from Colombian clinical isolates. 2017–2018 MMR Rojas, C López, J Ruiz, J Pavía, J Oñate, C Hernández-Gómez Open Forum Infectious Diseases 6 (Supplement_2), S858-S858, 2019 | 1 | 2019 |
| 1581. Comparative In Vitro Activity of Ceftolozane/tazobactam and Comparator Agents Against Enterobacteriaceae and Pseudomonas Aeruginosa Clinical … C Hernández-Gómez, E De La Cadena, MF Mojica, A Correa, ... Open Forum Infectious Diseases 6 (Supplement_2), S577-S577, 2019 | | 2019 |
| Cost-Effectiveness of Ceftolozane/Tazobactam Plus Metronidazole as Empiric Therapy for the Treatment of Complicated Intra-Abdominal Infections in Colombia P Lasalvia, D Rosselli, C Castañeda-Cardona, J Garzon, F Hernández, ... Value in Health 21, S152-S153, 2018 | | 2018 |
| Cost-Effectiveness of Ceftolozane/Tazobactam as Empiric Therapy for the Treatment of Complicated Urinary Tract Infections in Colombia P Lasalvia, D Rosselli, C Castañeda-Cardona, J Garzon, F Hernández, ... Value in Health 21, S152, 2018 | | 2018 |
Mónica RojasMSD ColombiaDirección de correo verificada de merck.com
